The fact that oncology-focused biopharmaceutical company Tesaro Inc., of Waltham, Mass., completed a successful and oversubscribed initial public offering (IPO) that was within its expected price range could be a sign of better things to come in the second half of the year for biotech companies now positioned on the IPO runway.